{"id":"W4401514694","doi":"10.1200/jco.2024.42.23_suppl.108","title":"Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Urothelial cancer; Chemotherapy; Oncology; Internal medicine; Cancer; Metastatic Urothelial Carcinoma; Randomized controlled trial; Immunotherapy; Urothelial carcinoma; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004016801,0.001314711,0.001485628,0.0003924464,0.0003734802,0.0007712069,0.0006429217,0.001200811,0.006039181],"category_scores_gemma":[0.002815573,0.0003945924,0.002470891,0.0004910644,0.0006004921,0.0007547192,0.0006783077,0.002568172,0.0004983385],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005704095,"about_ca_system_score_gemma":0.0007811598,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005674606,"about_ca_topic_score_gemma":0.001088985,"domain_scores_codex":[0.998139,0.001332052,0.00008724264,0.0001535794,0.0001362393,0.0001518602],"domain_scores_gemma":[0.9981893,0.0005629736,0.0006657853,0.0000902026,0.00009952499,0.000392307],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9764768,0.003034477,0.002763191,0.0004772013,0.001473842,0.00004286104,0.00003634425,0.0008467719,0.0007749835,0.00006505661,0.001089912,0.01291853],"study_design_scores_gemma":[0.789699,0.1783272,0.02516636,0.00009956982,0.00267135,0.000130483,0.00004883849,0.001197129,0.0006926051,0.000263925,0.001675584,0.00002792072],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836367,0.002993128,0.0005449739,0.0005123715,0.0001752234,0.004107174,0.005873531,0.00004575482,0.002111215],"genre_scores_gemma":[0.9833547,0.001399352,0.001039558,0.0006663238,0.0002022811,0.007127583,0.004812773,0.00001667336,0.001380643],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006039181,"threshold_uncertainty_score":0.02124316,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09391004980722414,"score_gpt":0.4765821723379932,"score_spread":0.382672122530769,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}